Table 2.
Clinical and laboratory characteristics of participants with different severity.
| Mild cases (n = 422) | Severe cases (n = 20) | All cases (N = 442) | Controls (N = 428) | |
|---|---|---|---|---|
| Male Proportion (%) | 63.27% | 90.00% | 64.48% | / |
| Age(mean (range)) | 52.15 (19–94) | 53.60 (25–80) | 52.21 (19–94) | / |
| Symptom (n(%)) | ||||
| Malaise | 195 (46.21%) | 18 (90.00%) | 213 (48.19%) | / |
| Loss of appetite | 185 (43.84%) | 15 (75.00%) | 200 (45.25%) | / |
| Nausea | 128 (30.33%) | 10 (50.00%) | 138 (31.22%) | / |
| Tired of greasy and bloating | 88 (20.85%) | 9 (45.00%) | 97 (21.95%) | / |
| Tea-colored urine | 75 (17.77%) | 10 (50.00%) | 85 (19.23%) | / |
| Scleral icterus | 68 (16.11%) | 10 (50.00%) | 78 (17.64%) | / |
| Fever | 58 (13.74%) | 4 (20.00%) | 62 (14.03%) | / |
| Loose stools | 40 (9.48%) | 3 (15.00%) | 43 (9.73%) | / |
| Liver area pain | 33 (7.82%) | 1 (5.00%) | 34 (7.69%) | / |
| Hepatomegaly | 18 (4.27%) | 0 (0.00%) | 18 (4.07%) | / |
| Liver palm | 6 (1.42%) | 0 (0.00%) | 6 (1.36%) | / |
| Splenomegaly | 4 (0.95%) | 0 (0.00%) | 4 (0.90%) | / |
| Spider nevi | 3 (0.71%) | 0 (0.00%) | 3 (0.68%) | / |
| Laboratory test results (n(%)) | ||||
| ALT (U/L)* | 552.60 (10.5–9,613),256 | 1509.5 (85–4,260),20 | 621.94 (10.5–9,613),276 | 23.72 (6–51),86 |
| AST (U/L)* | 333.14 (12–5,091),112 | 862.31 (40–2,787),16 | 411.53 (12–5,091),128 | 20.91 (0–42),55 |
| Total bilirubin (μmol/L)* | 58.75 (5.9–901),115 | 246.22 (171–602),20 | 86.52 (5.9–901),135 | 15.02 (4.2–142),54 |
| HBsAg | 7 (1.66%) | 2 (0.00%) | 9 (2.04%) | 0 (0.00%) |
| Anti-HBs | 9 (2.13%) | 1 (5.00%) | 10 (2.26%) | 2 (0.47%) |
| HBeAg | 1 (0.24%) | 1 (5.00%) | 2 (0.45%) | 0 (0.00%) |
| Anti-HBe | 5 (1.18%) | 0 (0.00%) | 5 (1.13%) | 0 (0.00%) |
| Anti-HBc IgM | 10(%) | 0 (0.00%) | 10 (2.26%) | 0 (0.00%) |
The symbol “*” indicates that the data in the corresponding cell are presented as mean (range), and the total number of participants who underwent the relevant test.